Anti-cancer agents from natural sources: A review

A.G. Nerkar, G.S. Chakraborthy, R. D. Ukirde

doi:10.18231/j.ctppc.2021.011

Visibility 7 Views
Downloads 3 Downloads
DOI 10.18231/j.ctppc.2021.011
CrossMark
Citation

Anti-cancer agents from natural sources: A review

Author Details:

A.G. Nerkar ^*

G.S. Chakraborthy

R. D. Ukirde

View PDF

Introduction

The drugs from the natural origin, i.e. natural products have played significant role in treatment of human ailments. Since ancient times the use of salicylates for the treatment of pain from the willow and the quinine from cinchona for the treatment of malaria are the most prevalent examples for the use of natural products in treatment of human infections and ailments. The projected incidence of patients with cancer in India among males was 679,421 (94.1 per 100,000) and among females 712,758 (103.6 per 100,000) for the year 2020. One in 68 males (lung cancer), 1 in 29 females (breast cancer), and 1 in 9 Indians will develop cancer during their lifetime.^[1] Cancer chemoprevention uses medicines from the synthetic or natural origin to inhibit, retard, or reverse the process of carcinogenesis.^[2], ^[3], ^[4] The natural product use for therapeutics is still one of the most prevalent in addition to the traditional remedies as exemplified by the legendary discovery of penicillin. Drugs from natural origin still comprise a large part of the day to day therapies. The vaccine development for the cancer is still a dream however for certain cancers such as cervical cancers the vaccines are available.^[5], ^[6] The cancer chemotherapy depends on the early diagnosis, treatment in cases of non-metastatic cancers and solely on chemotherapy for the metastatic cancers. The role of drugs of natural origin and their use in cancer has been overviewed.

Cancer Chemotherapy and the Role of Natural Products

Over 60% of the current anticancer drugs were derived in one way or another from natural sources. Nature is full of abundance with natural compounds with active chemical constituents that may effectively work against cancer. There are some methodologies that are being followed for to the natural product drugs for the treatment of cancer and these include one of the following methods:

Extract:^[7], ^[8], ^[9] Sometimes the part of plant extract is being used for the treatment of cancers as the case may be, however this type methodology is least followed now a day in allopathic practice where the active constituent must be labelled. However, this type of formulation is most commonly seen in Ayurveda.^[10], ^[11]

Isolate: This is label claim and most of the extracts have been isolated to their active constituent for the treatment of the cancer and widely accepted practice according to any FDA regulation.^[12], ^[13], ^[14], ^[15]

Semi-synthetic modification: The most of the active constituents after they have been isolated are semi-synthetically modified to give rise to the form of semisynthetic natural product for the cancer therapeutics.^[16], ^[17], ^[18], ^[19]

Synthetic modification: The new advances in synthetic chemistry of natural products and drug design have been enabling the total synthesis of the many natural products and these can be used where the amount of actual natural product isolate is very low.^[20], ^[21], ^[22]

Formulation improvements: Most of the natural products are poorly soluble and cannot be absorbed from the GI tract, in such cases many formulation improvements are being made so that these drugs become more absorbable and more patient compliant.^[23], ^[24], ^[25]

Conjugates: Tagging of natural products with the monoclonal antibodies is being practiced and it has been shown to be effective in treatment and targeting the epitopes on the tumor.

It should be noted that effective cancer chemotherapy often involves the use of combinations of several agents (so-called combination chemotherapy), and these combination regimens can comprise agents derived from both natural and synthetic sources.^[26], ^[27], ^[28]

Terrestrial plants as anti-cancer agents^[29], ^[30], ^[31]

Historically, successfully implementation of some terrestrial plant derived agents have been sought and these plant-derived agents include VBL and vincristine (VCR), etoposide, paclitaxel, docetaxel, topotecan, and irinotecan, are among the most effective cancer chemotherapeutics currently available. However the they come with side effects of toxicity and formulation problems such as poor solubility and have been succeeded and widely used in chemotherapeutics for the cancer treatment. Vinca Alkaloids^[32], ^[33]

Vincristine and vinblastine

The plant was used by various cultures for the treatment of diabetes, however when extracts were investigated in rats, they were found to demonstrate reduction in white blood cell count and showed profound bone depression.

Vincristine and Vinblastine are alkaloids derived from the plant, Catharanthus roseus G. Don. (Apocynaceae), a Madagascar periwinkle. Also known as Vinca alkaloids. They are active against lymphocytic leukemia in mice. Mechanism of action is disruption of microtubules causing arrest of cells at metaphase and apoptotic cell death.

Semisynthetic analogues^[34], ^[35]

The effective semisynthetic analogues that have been developed include vinorelbine and vindesine, with the most recent being vinflunine, a second-generation bifluorinated analogue of vinorelbine. Anhydrovinblsatine belongs to the class of organic compounds known as vinca alkaloids. These are alkaloids with a dimeric chemical structure composed of an indole nucleus (catharanthine), and a dihydroindole nucleus (vindoline), joined together.

Uses

In combination with other chemotherapeutic agents used for variety of malignancies such as leukemias, lymphomas, advanced testicular cancer, breast and lung cancers, and Kaposi’s sarcoma. Podophyllotoxins^[36], ^[37]

Etoposide and teniposide

It was used in Indian subcontinent as Podophyllum emodii Wallich for treatment of skin cancers and warts. First isolated in 1880 and was then later reported in 1950s. Also obtained from the species Podophyllum peltatum L.(commonly known as the American mandrake or mayapple).

Clinical trials of several closely related podophyllotoxin-like lignans, however, failed due to lack of efficacy and unacceptable toxicity. The extensive research on the structure led to the development of etoposide and teniposide as clinically effective agents. Mechanism of action shows that , podophyllotoxin reversibly binds to tubulin, etoposide and teniposide inhibit topoisomerase II, inducing topoisomerase II-mediated DNA cleavage.

Uses

Lymphomas, and bronchial and testicular cancers.Taxanes ^[38], ^[39], ^[40], ^[41]

In Ayurvedic medicine system, Taxus baccata is used for the treatment of the cancers. Other sources of the Taxanes which include placlitaxel and obtained and isolated from originally isolated from the bark of the Pacific yew, Taxus brevifolia Nutt. (Taxaceae), and docetaxel , a semisynthetic analogue synthesized from DAB (10-deacetylbaccatin III) isolated from the leaves of the European yew, Taxus baccata.

Paclitaxel and docetaxel

DAB is semi-synthetically converted to paclitaxel. Mechanism of action of these taxane derivatives is that they promote the polymerization of tubulin heterodimers to microtubules, suppressing dynamic changes in microtubules resulting in mitotic arrest.

Uses

It is used in treatment of breast, ovarian, and non-small cell lung cancer (NSCLC), and has also shown efficacy against Kaposi’s sarcoma, while docetaxel is primarily used in the treatment of breast cancer and NSCLC.

Substantial synthetic modifications in the structure of taxanes have resulted in the development of variety of analogues. Some of the clinical limitations of paclitaxel and docetaxel, include poor solubility, allergic reactions, dose-limiting toxicities such as myelosuppression or peripheral sensory neuropathy, and the development of drug resistance due to P-glycoprotein-mediated efflux. Cabazitaxel^[42] It is approved for the treatment of metastatic prostate cancer (in combination with prednisone and/or prednisolone).

Some of the structural analogues in clinical development are given as follows:Taxoprexin ^[43] or 7-docosahexaenoic acid (DHA)-paclitaxel (Protarga), a prodrug of paclitaxel covalently bound to the naturally occurring ω-3 fatty acid DHA which enables delivery directly to tumor tissue.

Larotaxel (XRP9881); Ortataxel: ^[44] Tesetaxel: ^[45] (DJ-927); TPI-287, and paclitaxel poliglumex (PPX, CT-2103) an α-poly- L –glutamic acid conjugate of paclitaxel. ^[46] It is a potent radiation sensitizer, possibly enhancing radiation for glioblastoma.

The approved formulations of nanoparticle paclitaxel are mentioned as follows:

Nab-paclitaxel

It is an albumin-stabilized nanoparticle formulated without the use of emulsifying agent.

Cremophor (polyethoxylated castor oil):^[47]

It is a formulation of paclitaxel enabling larger doses of paclitaxel to be administered while avoiding the toxic effects associated with Cremophor.

Uses

It is used in refractory breast cancer, NSCLC, and pancreatic cancer as a less toxic agent, although it is less effective, alternative to the 4-drug regimen (leucovorin, 5-FU, irinotecan, and oxaliplatin).

Genexol-PM:^[47], ^[48]

A Cremophor EL-free polymeric micelle formulation of paclitaxel, which has shown activity against gemcitabine sensitive and -resistant pancreatic ductal adenocarcinoma cell lines.

Tocosol (S-8184):^[49]

A tocopherol based Cremophor-free formulation of paclitaxel It has higher bioavailability of unbound paclitaxel compared to Cremophor EL-formulateed paclitaxel.

Camptothecins^[50]

The source for Camptothecins (CPTs) as active constituent is the Chinese ornamental tree Camptotheca acuminata Decne (Nyssaceae). The acts by binding to the topoisomerase I-DNA binary complex resulting in a stable ternary complex, thereby preventing DNA religation

and causing DNA damage, which results in apoptosis. The water-soluble sodium salt in the 1970s, was discovered and clinical trials however, were terminated due to severe bladder toxicity. Comprehensive reviews of CPT and its analogues have been published. The chemical structure study and modifications led to the development of semisynthetic derivatives, topotecan, irinotecan and belotecan , approved for clinical use. To avoid the problems of bioavailability , toxicity and pharmacokinitetics, many structural analogues of CPT have been designed and developed.

Cositecan and silatecan (AR-67)

These are lipophilic silicon-containing CPTs modified in the gimatecan 7-position ^[51], ^[52]

Diflomotecan and derivatives ((BN80915), 10,11-difluorohomo CPT)^[53], ^[54]

It is Water-soluble diflomotecan analogue currently in clinical development are the hydrochloride salts of elemotecan, lurtotecan, and namitecan, as well as DRF-1042.

SN-38 (7-ethyl-10-hydroxy CPT)^[55]

It is a poorly soluble in water and pharmaceutically approved solvents. The extensive research on formulation using macromolecules and these agents for delivery to the cancer cells and tissues, thus improving efficacy and reducing side effects.

Products derived from CPT^[56]

CRLX101

It is conjugated form of polymeric nanoparticle cyclodextrinpoly(ethylene glycol) copolymer, with apparent solubility increase of >1,000-fold as compared to CPT. It shows excellent safety, pharmacokinetic, and efficacy results in an early clinical trials in patients with advanced solid malignancies.

XMT-1001 (MER-1001 or PHF-CPT)

It is a novel, water-soluble macromolecular prodrug of CPT (molecular weight:70 kDa), in which CPT is conjugated to a hydrophilic, biodegradable polyacetal polymer, poly(1-hydroxymethylethylene hydroxymethylformal), also known as PHF and is slowly released.

Combretastatins^[57]

The combretastatins are a family of stilbenes originally isolated from the root bark Combretum caffrum, also known as the Cape bush willow in southern Africa. Mechanism of action of the drugs include it act as vascular disrupting agents, selectively targeting the endothelial cells lining the tumor vasculature. They also disrupt the tubulin cytoskeleton and remodel the actin cytoskeleton, inducing a significant change in the three-dimensional shape of immature endothelial cells, thereby stopping blood flow through the capillary and starving the tumor of nutrients, causing tumor cell death. This mechanism of action differentiates the combretastatins from angiogenesis inhibitors that are designed to work by preventing the growth of new blood vessels.

Combretastatin prodrugs^[58]

Combretastatin A4 phosphate is a phosphate prodrug of CA4. It was granted orphan drug status for the treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer. Used for the treatment of ovarian cancer, and treatment of patients with platinum-resistant ovarian cancer with a combination of CA4P, carboplatin. Numerous analogues of Combretastatin A4 phopsphate such as Combretastatin A1 diphosphate is a phosphate prodrug of CA1 ,and found to be promising in relapsed and refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome patients . It received orphan drug designation for the treatment of AML.

Homoharringtonine (HHT) (Omacetaxine Mepesuccinate)^[59], ^[60]

It was isolated first in 1970 from the Chinese tree, Cephalotaxus harringtonia var. drupacea (Sieb and Zucc.; Cephalotaxaceae). The bark of this plant was used in traditional medicine in china for various conditions. In 1983, it was reported to have significant cytotoxicity of the total alkaloid fraction of Cephalotaxus fortunei Hook F. A racemic mixture of HHT and harringtonine has been used in China for the treatment of AML and chronic myelogenous leukemia (CML). The principal mechanism of action of HHT is the inhibition of protein synthesis in a dose- and time-dependent manner by acting on the ribosomes of cancer cells. It blocks the progression of cells from G1 phase into S phase and from G2 phase into M phase. It is showed synergestic or additive in vitro with AraC, amsacrine, actinomycin D and dexamethasone. Clinical studies have indicated that HHT is effective in treating acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS), but not acute lymphoblastic leukemia (ALL) and solid tumors. The dose limiting toxicities are hypotention and myelosuppression. Homoharringtonine has relatively mild extramedullary toxicities and no anthracycline-like cardiac toxicity, which make it a suitable candidate for the treatment of aged patients. Pharmacological studies indicate that HHT belongs to the category of multidrug resistance (MDR)-related drugs.

Ingenol Mebutate (Ingenol-3-Angelate)^[61], ^[62]

It is obtained from the plant Euphorbia peplus (Euphorbiaceae) is widely used as a home remedy for the treatment of various skin conditions, and clinical studies. The crude E. peplus sap in the 1970s showed positive and promising pharmacological activity. The active chemical constituents include hydrophobic diterpene ester, ingenol-3-angelate (PEP005; ingenol-3-mebutate; Picato. It is believed to act through activation of protein kinase C(PKC). FDA approved it in year 2012, as a topical gel formulation (Picato) for the EMA.

Anticancer agents discovered from marine source^[63]

Sea covers 70% of the planet and out of which less than 5% have been explored for the pharmacological activity and less than 0.01% of the deep sea have been explored for the pharmacological flora and fauna. Only 4 drugs from the marine origin have been approved for the human use which are from the marine origin. Although several isolates from the marine sources are explored. These agents are cytarabine (AraC), trabectedin, eribulin which is a synthetic derivative.

Cytarabine and nucleoside analogues^[64]

Tethya crypta a marine Caribbean sponge was extracted the two bioactive nucleosides such as spongothymididne and spongouridine, discovered by Bergmann and Burke in the early 1950s this led to further exploration of marine environment for the drug discovery. Thus, cytarabine (AraC) a potent antileukemic agent, and the antiviral agent, AraA (adenine arabinoside) were discovered. This further led to the development of various nucleoside analogues showing significant anticancer activity which were developed later.

Clofarabine

In 2004, Clofarabine a second-generation antileukemic agent was approved which has significant safety and efficacy. Used for the treatment of pediatric patients with acute lymphoblastic leukemia, further clinical trials are in process. In addition, its role in the treatment of adult patients with acute myeloid leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia and the myelodysplastic syndrome has shown positive results. ^[65], ^[66]

Sapacitabine (CYC-682)^[67]

It is an orally bioavailable nucleoside analogue prodrug. Mechanism of action includes breaking of the single-strand after incorporation into DNA, which are converted into double- strand break at the S phase of cell cycle. It has been shown to be active in the treatment of elderly patients with AML. It received orphan drug designation for the treatment of AML and for the treatment of myelodysplastic syndromes in 2010.

Trabectedin^[68]

The structure of ecteinascidin derivatives was isolatded and discovered in 1986 however trabectedin the most active of the ecteinascidins, was reported in 1990. It was the first ‘unmodified’ marine-derived natural product to be approved for the treatment of cancer, and it is undergoing

clinical trials for the treatment of breast, prostate, and pediatric sarcomas.

Uses

Used in advanced soft-tissue sarcoma and ovarian cancer by the FDA and the EMA.

Zalypsis (PM-10450) and lurbinectedin (PM-01183)^[69], ^[70]

They have progressed into clinical trials, and their discovery and development have been discussed. It blocks the oncogenic transcription factor FUS-CHOP and reverses the transcriptional program in myxoid liposarcoma. It reverses the genetic program created by this transcription factor, trabectedin promotes differentiation and reverses the oncogenic phenotype in these cells. Other mechanism of action known are it binds and alkylate DNA at the N2 position of guanine. It is known from in vitro work that this binding occurs in the minor groove, spans approximately three to five bpbase pairs and is most efficient with CGG sequences. Additional binding sequences are TGG, AGC, or GGC. Once bound, this reversible covalent adduct bends DNA toward the major groove, interferes directly with activated transcription, poisons the transcription-coupled nucleotide excision repair complex, promotes degradation of RNA polymerase II, and generates DNA double-strand breaks.

Halichondrin B and Eribulin^[71], ^[72]

The segregation and underlying explanation of the intricate regular item, halichondrin B, alongside a few other halichondrin subsidiaries, were first revealed from the marine wipe Halichondriaokadaiin 1986, and firmly followed by reports of the detachment of similar series of mixtures from various wipes gathered in various regions, going from the Central Pacific to the Indian Ocean to waters off New Zealand. It was displayed to go about as a tubulin-weakening specialist and was supported for preclinical improvement by the US National Cancer Institute in mid 1992. The acquirement of adequate supplies of source crude material end up being testing, however enormous scope assortments and in-ocean hydroponics of the wipe Lissodendoryx sp continued off the shoreline of New Zealand as a team with nearby researchers, and adequate amounts of halichondrin B were disengaged for preclinical investigations. In the meantime, quite a while before its endorsement for preclinical turn of investigating the absolute combination of halichondrin B, and, in 1992, they revealed that they had integrated halichondrin B and norhalichondrin B. Working as a team with researchers at the then Eisai Research Institute, the natural not really settled to dwell predominately in the ring piece of the atom, and near 200 subordinates of the shortened regular item were made and assessed. Straight on correlations of unadulterated halichondrin B and the best manufactured analogs, utilizing in vitro time course tests and in vivo concentrates in mice with human xenografts, showed that the shortened halichondrin B simple, presently known as eribulin, with underlying similitudes to halichondrin B showed altogether more intense movement in the in vivo contemplates. This compound was picked for cutting edge preclinical and afterward clinical examinations, utilizing materials made under cGMP conditions by absolute combination. Following broadened clinical preliminaries, eribulin was endorsed for the therapy of headstrong bosom malignancy by the FDA in 2010. The disclosure and improvement of this compound, including the movement from the combination of halichondrin B to the underlying union of eribulin, have been checked. Moreover, papers on the modern strategies that empowered the enormous scope creation of eribulin have been distributed. Until now, eribulin is by a wide margin the most perplexing medication at any point created by absolute blend, and it is a demonstration of the entirety of the specialists in three nations and different associations that coordinated to make it a triumph.

Anti-cancer agents derived from bacteria and fungi^[73]

Antitumor antibiotics are amongst the most important of the cancer chemotherapeutic agents. These include members of the actinomycin, ansamycin, anthracycline, bleomycin, epothilone, and staurosporin classes. Except for the epothilones, which are metabolites of the myxobacterium Sorangium cellulosum, metabolites of the other classes were isolated from various Streptomyces species.

Rapamycin^[74], ^[75], ^[76], ^[77]

The discovery of rapamycin 31-membered macrocyclic antibiotic produced by the fermentation of a strain of Streptomyces hygroscopicus isolated from soil samples in Rapa Nui (Easter Island), was first reported in 1975. Initially reported to have antifungal activity, it was approved for use as an immunosuppressive agent (trade name, Rapamune) in 1999. While reported to have antitumor activity in 1984, only reports of the identification of TOR (‘target of rapamycin’) as the molecular target in yeast in 1991, followed by mTOR as the mammalian homologue in 1994, ultimately led to the development of a wide variety of anticancer and other pharmacologic agents.

Chemical modifications have yielded two clinically approved anticancer drugs.

Everolimus: It was initially approved as an immunosuppressive agent in 2004, but approval was granted for the treatment of kidney, brain, pancreatic, and breast cancers in 2009, 2010, 2011, and 2012, respectively. It is also currently in, or has recently completed, phase III trials for treating diffuse large B-cell lymphoma (NCT00790036), liver (NCT01035229), and stomach (NCT00879333) cancers.

Temsirolimus: It was first approved as a treatment for renal carcinoma in 2007 and is currently in phase II trials for the treatment of various carcinomas. Another rapamycin derivative showing promise in the treatment of cancer is ridaforolimus, which has recently completed a phase III trial for the treatment of soft-tissue carcinoma and bone cancer.

Carfilzomib (Kyprolis TM): It is a synthetic analogue of epoxomicin, a peptide α ′ ,β ′ -epoxyketone isolated from an actinomycete strain, is a proteasome inhibitor which binds through a covalent, selective, and stereospecific linkage to the chymotryptic subunit (20S) of the proteasome. Uses: Refractory multiple myeloma who had received prior treatment with bortezomib, thalidomide, or lenalidomide.

Midostaurin: It is a semisynthetic derivative of staurosporine, an indolocarbazole alkaloid isolated from Streptomyces staurosporeus. It is sold under the brand name Rydapt & Tauritmo both by Novartis. It works as a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Specific target agents

Maytansinoids^[78]

Maytansine , a novel macrocyclic compound, was secluded in very low yield in the mid 1960s from the Ethiopian plant, Maytenusserrata (Hochst. ex A. Rich.) Wilczek Derivatives of maitansine are known as maytansinoids. Some are being explored as the cytotoxic part of counter acting agent drug forms for disease therapy and the immune response drug form trastuzumabemtansine is a supported medication for the therapy of particular sorts of bosom malignancy in the EU and in the US. They have primary comparability to the 'ansa' anti-microbials, for example, the rifamycins; normal item physicists had contemplated whether maytansine was of microbial beginning.

Ansamitocins^[79]

In 1977, the seclusion of the firmly related ansamitocins from the bacterium Actinosynnemapretiosum. The ansamitocins gave a prepared and manageable wellspring of maytansinoids, and the subordinates DM1 and DM4 have been arranged from suitable ansamitocins. Formation with Monoclonal Antibodies DM1 and DM4 have been formed through either thioether or disulfide linkages with different monoclonal antibodies focusing on an assortment of tumors.

T-DM1: Linkage of DM1 to the endorsed her2neu - designated immunizer, trastuzumab, gives T-DM1 or ado-trastuzumabemtansine.

Uses

It showed huge adequacy in the therapy of patients with cutting edge for metastatic HER2-positive bosom malignancy who had flopped somewhere around two medicines with the at present supported medications, trastuzumab and the tyrosine kinase inhibitor lapatinib.

Brentuximab vedotin^[80]

Brentuximab vedotin is framed by formation of monomethyl auristatin E (vedotin), got from dolastatin 10, an optional metabolite initially disengaged from the marine mollusk, Dolabellaauricularia, yet later segregated from a Symploca types of cyanophyte which was demonstrated to be in the eating regimen of the mollusk.

Uses

CD30-positive lymphoproliferative issues like Hodgkin's lymphoma, EMA in 2011 and 2012, individually. The formation of vedotin or firmly related analogs with antibodies focusing on epitopes found in different tumors, including breast, gastrointestinal, pancreatic, prostate, ovarian and renal malignant growths, leukemias, melanomas and NSCLC are under clinical preliminaries.

Discovery and evaluation of anti-cancer agents from natural sources^[81]

From epidemiological studies it was evident that people with diet rich in fruits and vegetables are less prone to cancer and thus the chemotherapeutic agents were studied under clinical trials include β-carotene from carrots, lycopene from tomatoes, indoles from cruciferous vegetables, curcumin from turmeric, catechins from green tea, and anthocyanins from blueberries. Some clinical trials have failed with variety of agents and active constituents.

Drugs from natural origin currently in clinical trials^[82]

Other examples of natural product-derived agents in clinical trials include, Polyphenon E Retinoids, soy isoflavones, vitamin C, vitamin D, and vitamin E. In addition, curcumin has failed in clinical trials but the its derivatives are still under clinical trials.

Cancer chemopreventive agents from natural source^[83], ^[84]

A traditionally Taxol and CPT isolation and bioassay has led to discovery of several natural products that are chemo-preventive. Similar approach towards the development of anticancer agents has been studied using epigenetic pathways or signaling pathways including Keap1-Nrf2, and the Keap1-Nrf2-ARE signaling pathway and led to the discovery very useful agents.

Repurposing

Using this strategy, the active constituents from dietary natural products, nondietary natural products, semisynthetic derivatives, and known natural products with hitherto unknown mechanism of action. A resounding example of the latter is the quassinoid bruceantin and the close structural relative brusatol have been discovered.

Bruceantin

It was originally discovered as a cancer chemotherapeutic agent and dropped due to poor efficacy in advanced-stage cancer patients. It is a potent inducer of cell differentiation and subsequently found to inhibit tumor growth at low doses in the absence of toxicity.^[85]

Resveratrol

It was isolated from a nonedible legume following bioassay-guided fractionation with inhibition of cyclooxygenase as the objective. It is inhibitor of skin carcinogenesis functioning by a pleiotropic mechanism of action. It is a constituent of grapes and grape wine, thus this industry received substantial importance in past years.^[86]

Conclusion

The natural products have been used for both chemoprevention and chemotherapeutics. The natural products from terrestrial, marine and microbial sources have been reviewed and discussed in this review. Further anticancer drug evaluation from dietary sources have also been discussed. Farther the vaccine development for cancer excluding some cancers, the natural products have been more affordable and easily available therapies for cancer. Whether in extract, isolate, synthetic, semisynthetic, improved formulations or as a conjugate, the natural products have served the purpose of life saving and improving the quality of life in many cases.

Source of Funding

None.

Conflict of Interest

None.

References

P Mathur, K Sathishkumar, M Chaturvedi, P Das, K L Sudarshan, S Santhappan. Report From National Cancer Registry Programme. 2020. [Google Scholar]
X Wu, S M Lippman. An intermittent approach for cancer chemoprevention. Nat Rev Cancer 2011. [Google Scholar] [Crossref]
R G Mehta, G Murillo, R Naithani, X Peng. Cancer chemoprevention by natural products: how far have we come?. Pharm Res 2010. [Google Scholar] [Crossref]
T Tanaka. Cancer chemoprevention by natural-products. Oncol Rep 1994. [Google Scholar]
M Vergati, C Intrivici, N Y Huen, J Schlom, K Y Tsang. Strategies for cancer vaccine development. J Biomed Biotechnol 2010. [Google Scholar] [Crossref]
X Yin, J Zhou, C Jie, D Xing, Y Zhang. Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549. Life Sci 2004. [Google Scholar] [Crossref]
J Wu, Y Wu, B B Yang. Anticancer activity of Hemsleya amabilis extract. Life Sci 2002. [Google Scholar] [Crossref]
P Houghton, R Fang, I Techatanawat, G Steventon, P J Hylands, C C Lee. The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity. Methods 2007. [Google Scholar] [Crossref]
K Zandi, S Ahmadzadeh, S Tajbakhsh, Z Rastian, F Yousefi, F Farshadpour. Anticancer activity of Sargassum oligocystum water extract against human cancer cell lines. Eur Rev Med Pharmacol Sci 2010. [Google Scholar]
S N Gaidhani, G S Lavekar, A S Juvekar, S Sen, A Singh, S Kumari. In-vitro anticancer activity of standard extracts used in ayurveda. Pharmacognosy Mag 2009. [Google Scholar]
P Balachandran, R Govindarajan. Cancer-an ayurvedic perspective. Pharmacol Res 2005. [Google Scholar] [Crossref]
P Li, L Liu, S Huang, Y Zhang, J Xu, Z Zhang. Anti-cancer Effects of a Neutral Triterpene Fraction from Ganoderma lucidum and its Active Constituents on SW620 Human Colorectal Cancer Cells. Anticancer Agents Med Chem 2020. [Google Scholar] [Crossref]
A Aniqa, S Kaur, S Sadwal. A Review of the Anti-Cancer Potential of Murraya koenigii (Curry Tree) and Its Active Constituents. Nutr Cancer 2021. [Google Scholar]
H C Wang, C C Wu, T S Cheng, C Y Kuo, Y C Tsai, S Y Chiang. Active Constituents from Liriope platyphylla Root against Cancer Growth In Vitro. Integr Oncol 2013. [Google Scholar] [Crossref]
L K Lam, V L Sparnins, L W Wattenberg. Isolation and identification of kahweol palmitate and cafestol palmitate as active constituents of green coffee beans that enhance glutathione S-transferase activity in the mouse. Cancer Res 1982. [Google Scholar]
L L Dulcey, R Tomasin, M A Naves, J A Da Silva, M R Cominetti. Autophagy-dependent apoptosis is triggered by a semi-synthetic [6]-gingerol analogue in triple negative breast cancer cells. Oncotarget 2018. [Google Scholar] [Crossref]
V A Silva, M N Rosa, O Martinho, A Tanuri, J P Lima, L F Pianowski. Modified ingenol semi-synthetic derivatives from Euphorbia tirucalli induce cytotoxicity on a large panel of human cancer cell lines. nvest New Drugs 2019. [Google Scholar] [Crossref]
A K Mukherjee, S Basu, N Sarkar, A C Ghosh. Advances in cancer therapy with plant based natural products. Curr Med Chem 2001. [Google Scholar] [Crossref]
I T Silva, F C Geller, L Persich, S E Dudek, K L Lang, M S Caro. Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549. Invest Drugs 2016. [Google Scholar] [Crossref]
E Marchal, S Rastogi, A Thompson, J T Davis. Influence of B-ring modifications on proton affinity, transmembrane anion transport and anti-cancer properties of synthetic prodigiosenes. Organ Biomol Chem 2014. [Google Scholar]
J E Audia, R M Campbell. Histone Modifications and Cancer. Cold Spring Harb Perspect Biol 2016. [Google Scholar] [Crossref]
P Purushottamachar, A M Godbole, L K Gediya, M S Martin, T S Vasaitis, A K K Afful. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem 2013. [Google Scholar] [Crossref]
R Pangeni, L Subedi, S K Jha, S Kweon, S H Kang, K Y Chang. Improvements in the Oral Absorption and Anticancer Efficacy of an Oxaliplatin-Loaded Solid Formulation: Pharmacokinetic Properties in Rats and Nonhuman Primates and the Effects of Oral Metronomic Dosing on Colorectal Cancer. Int J Nanomedicine 2020. [Google Scholar] [Crossref]
J E Fardell, B Thewes, J Turner, J Gilchrist, L Sharpe, A Girgis. Fear of cancer recurrence: a theoretical review and novel cognitive processing formulation. J Cancer Survivorship 2016. [Google Scholar] [Crossref]
C L Messerer, E C Ramsay, D Waterhouse, R Ng, E M Simms, N Harasym. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 2004. [Google Scholar] [Crossref]
C H Chau, P S Steeg, W D Figg. Antibody–drug conjugates for cancer. Lancet 2019. [Google Scholar] [Crossref]
E L Sievers, P D Senter. Antibody-drug conjugates in cancer therapy. Annual review of medicine. Annual Rev Med 2013. [Google Scholar] [Crossref]
R V Chari, M L Miller, W C Widdison. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 2014. [Google Scholar] [Crossref]
J Mann. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2002. [Google Scholar]
G M Cragg, J M Pezzuto. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract 2016. [Google Scholar] [Crossref]
S E Kintzios. Terrestrial plant-derived anticancer agents and plant species used in anticancer research. Crit Rev Plant Sci 2006. [Google Scholar] [Crossref]
M Moudi, R Go, C Y Yien, M Nazre. Vinca alkaloids. Int J Prev Med 2013. [Google Scholar]
M A Jordan, D Thrower, L Wilson. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991. [Google Scholar]
C Lopez, B Claude, P Morin, J P Max, R Pena, J P Ribet. Synthesis and study of a molecularly imprinted polymer for the specific extraction of indole alkaloids from Catharanthus roseus extracts. Anal Chim acta 2011. [Google Scholar] [Crossref]
E Giovanelli, L Moisan, S Comesse, S Leroux, B Rousseau, P Hellier. Synthesis of fluorinated catharanthine analogues and investigation of their biomimetic coupling with vindoline. Organ Biomol Chem 2013. [Google Scholar]
M Gordaliza, P A Garcıa, D Corral, J M Castro, M A G Zurita, M A. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon 2004. [Google Scholar] [Crossref]
C Canel, R M Moraes, F E Dayan, D Ferreira. Podophyllotoxin. Phytochemistry 2000. [Google Scholar] [Crossref]
J Crown, O Leary. The taxanes: an update. Lancet 2000. [Google Scholar] [Crossref]
M T Huizing, V S Misser, R C Pieters, W B Huinink, C H Veenhof, J B Vermorken. Taxanes: a new class of antitumor agents. Cancer investig 1995. [Google Scholar] [Crossref]
B T Mcgrogan, B Gilmartin, D N Carney, A Mccann. Microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008. [Google Scholar] [Crossref]
De Bono, J S Oudard, S Ozguroglu, M Hansen, S Machiels, J P Kocak, i. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010. [Google Scholar] [Crossref]
C J Paller, E S Antonarakis. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 2011. [Google Scholar] [Crossref]
V Dieras, S Limentani, G Romieu, M T Hulin, A Lortholary, P Kaufman. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Annal oncol 2008. [Google Scholar] [Crossref]
M Beer, L Lenaz, D Amadori. Ortataxel Study Group. Phase II study of ortataxel in taxane-resistant breast cancer. J Clin Oncol 2008. [Google Scholar]
M Roche, H Kyriakou, M Seiden. Drug evaluation: tesetaxel--an oral semisynthetic taxane derivative. Current opinion in investigational drugs. 2000. [Google Scholar]
J W Singer, S Shaffer, B Baker, A Bernareggi, S Stromatt, D Nienstedt. Drug evaluation: tesetaxel--an oral semisynthetic taxane derivative. Curr Opin Investig Drugs 2005. [Google Scholar]
A Sparreboom, C D Scripture, V Trieu, P J Williams, T De, A Yang. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005. [Google Scholar] [Crossref]
T Y Kim, D W Kim, J Y Chung, S G Shin, S C Kim, D S Heo. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2014. [Google Scholar] [Crossref]
K Motamed, M Choi, V Trieu. Discordance Between Unbound Paclitaxel Plasma Levels and Efficacy-Lessons From Tocosol-Paclitaxel. Ann Oncol 2014. [Google Scholar] [Crossref]
C J Thomas, N J Rahier, S M Hecht. Camptothecin: current perspectives. Bioorg Med Chem 2004. [Google Scholar] [Crossref]
N F Lazareva, V P Baryshok, I M Lazarev. Silicon-containing analogs of camptothecin as anticancer agents. Arch Pharm 2018. [Google Scholar] [Crossref]
N J Rahier, C J Thomas, S M Hecht. Camptothecin and its analogs. 2005. [Google Scholar]
J R Kroep, H Gelderblom. Diflomotecan, a promising homocamptothecin for cancer therapy. Expert opin investig drugs 2009. [Google Scholar] [Crossref]
J S Graham, S Falk, L M Samuel, J M Cendros, T J Evans. A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy. Cancer Chemother Pharmacol 2009. [Google Scholar] [Crossref]
Y Kawato, M Aonuma, Y Hirota, H Kuga, K Sato. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991. [Google Scholar]
F Li, T Jiang, Q Li, X Ling. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer. Am J cancer Res 2017. [Google Scholar]
G C Tron, T Pirali, G Sorba, F Pagliai, S Busacca, A A Genazzani. Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 2006. [Google Scholar] [Crossref]
N H Nam. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr Med Chem 2003. [Google Scholar] [Crossref]
H M Kantarjian, M Talpaz, V Santini, A Murgo, B Cheson, O 'brien, S M. Homoharringtonine: History, current research, and future directions. Cancer 2001. [Google Scholar]
D C Zhou, R Zittoun, J P Marie. Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer 1995. [Google Scholar]
R S Fallen, M Gooderham. Ingenol mebutate: an introduction. Skin ther letter 2012. [Google Scholar]
M Lebwohl, N Swanson, L L Anderson, A Melgaard, Z Xu, B Berman. Ingenol mebutate gel for actinic keratosis. Engl J Med 2012. [Google Scholar]
G Schwartsmann, A B Rocha, R G Berlinck, J Jimeno. Marine organisms as a source of new anticancer agents. Lancet Oncol 2001. [Google Scholar] [Crossref]
M Barreca, V Spanò, A Montalbano, M Cueto, D Marrero, A R Deniz. Marine anticancer agents: an overview with a particular focus on their chemical classes. Mar Drugs 2020. [Google Scholar] [Crossref]
C H Pui, S Jeha, P Kirkpatrick, Clofarabine. Clofarabine. Nat Rev Drug Discov 2005. [Google Scholar] [Crossref]
H M Kantarjian, S Jeha, V Gandhi, M Wess, S Faderl. Clofarabine: past, present, and future. Leuk Lymphoma 2007. [Google Scholar] [Crossref]
J Rautio, J Kärkkäinen, K B Sloan. Prodrugs-Recent approvals and a glimpse of the pipeline. Eur J Pharm Sci 2017. [Google Scholar] [Crossref]
N J Carter, S J Keam. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007. [Google Scholar] [Crossref]
D J Newman, G M Cragg. Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development.. Mar drugs 2014. [Google Scholar] [Crossref]
D J Newman, G M Cragg. Drugs and drug candidates from marine sources: An assessment of the current “state of play”. . Planta med 2016. [Google Scholar] [Crossref]
R Bai, T L Nguyen, J C Burnett, O Atasoylu, M H Munro, G R Pettit. Interactions of halichondrin B and eribulin with tubulin. J Chem Inf modeling 2011. [Google Scholar] [Crossref]
J Cortes, L Vahdat, J L Blum, C Twelves, M Campone, H Roché. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010. [Google Scholar] [Crossref]
G M Cragg, P G Grothaus, D J Newman. Impact of natural products on developing new anti-cancer agents. Chem Revi 2009. [Google Scholar] [Crossref]
Z Zeng, D D Sarbassov, I J Samudio, K W Yee, M F Munsell, E Jackson. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007. [Google Scholar] [Crossref]
P A Lowden, G A Böhm, S Metcalfe, J Staunton, P F Leadlay. New rapamycin derivatives by precursor-directed biosynthesis. ChemBioChem 2004. [Google Scholar] [Crossref]
S R Edwards, T J Wandless. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem 2007. [Google Scholar] [Crossref]
B Nashan. Early clinical experience with a novel rapamycin derivative. Ther drug Monitoring 2002. [Google Scholar] [Crossref]
P J Reider. View on ScienceDirect The Alkaloids: Chemistry and Pharmacology. 1984. [Google Scholar]
E Higashide, M Asai, K Ootsu, S Tanida, Y Kozai, T Hasegawa. Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia. Nature 1977. [Google Scholar] [Crossref]
A Younes, U Yasothan, P Kirkpatrick. Brentuximab vedotin. Nat Rev Drug discov 2012. [Google Scholar]
M K Chahar, N Sharma, M P Dobhal, Y C Joshi. Flavonoids: A versatile source of anticancer drugs. Pharmacogn Rev 2011. [Google Scholar] [Crossref]
G Samuelsson, L Bohlin. Drugs of Natural Origin. 2017. [Google Scholar]
G Tan, C Gyllenhaal, D D Soejarto. Biodiversity as a source of anticancer drugs. Curr Drug Targets 2006. [Google Scholar] [Crossref]
T F Wong, K Yoshinaga, Y Monma, K Ito, H Niikura, S Nagase. Association of keap1 and nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival. Int J Gynecol Cancer 2011. [Google Scholar] [Crossref]
S M Kupchan, R W Britton, M F Ziegler, C W Sigel. Bruceantin, a new potent antileukemic simaroubolide from Brucea antidysenterica. J Organ Chem 1973. [Google Scholar] [Crossref]
L Frémont. Biological effects of resveratrol. Life Sci 2000. [Google Scholar] [Crossref]